Europe
In May the FDA placed a hold on the trial and IND for CTX001, an investigational gene editing treatment, citing concerns over questions that had not been addressed in the IND.
Vitaccess and Pharnext SA today announced the launch of an international study on Charcot Marie Tooth disease (CMT) using a bespoke digital app named CMT&Me.
Abcam’s new phosphate buffered saline (PBS)-only recombinant antibodies are free from preservatives and stabilising agents, offering improved flexibility for researchers conducting more complex experiments.
- Industry recognised accreditation for leading digital healthcare agency -
Clinigen Group plc announces that it has today completed the acquisition of iQone Healthcare Holding (‘iQone’), which was announced on 27 September 2018 (the “Acquisition”).
In August, Pfizer filed with the U.S. Food and Drug Administration (FDA) accusing Amgen and Roche of using social media to mislead doctors and patients about biosimilars and their effectiveness.
Celgene Corporation presented data at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Berlin, Germany with results from two Phase III trials.
A post-hoc analysis of a Phase II sickle cell disease study showed that patients treated with crizanlizumab significantly reduced occurrences of vaso-occlusive crisis, a serious disease complication that can lead to organ failure.
Genentech, a Roche company, released data from a long-term clinical trial of Ocrevus in multiple sclerosis. Meanwhile, Novartis isn’t standing still on MS. Earlier this week the company announced that both the FDA and EMA had accepted its NDA and MAA, respectively, for siponimod.
The neuroprotection biotech also strengthens its scientific team with the arrival of Dr. Amit Bar-Or, a multiple sclerosis specialist, to the Scientific Advisory Board
PRESS RELEASES